The NCE Standing Selection Committee is composed of international calibre experts with broad, multidisciplinary and multisectoral expertise, representing the domains of the three federal granting agencies, as well as the diversity of current government priority sectors. It reviews Letters of Intent (LOIs) and final applications for the Networks of Centres of Excellence (NCE), Knowledge Mobilization Initiative Networks (NCE-KM), Canada-India Research Centre of Excellence (CIRCE) and the NCE International Knowledge Translation Platforms (NCE-IKTP) initiative. The committee provides recommendations to the NCE Management Committee regarding which LOIs to advance to the full application stage of the competition, and recommends to the NCE Steering Committee which full applications should receive funding.
(Chair) Jane Barratt is the Secretary General of the International Federation on Ageing comprising government and non government members in 62 countries and representing some 50 million older people. She brings to this position over 35 years experience in both public and private sectors in the fields of public health, community and aged care, and ageing and disability. Dr Barratt has strived to strengthen the roles and relationships between government, NGOs, academia and the private sector in order to help shape and influence policy to improve the quality of life of older people. She is a strong contributor to the international dialogue on the intersection of social, cultural and physical environments that impact on the lives of older people. Dr Barratt is a Churchill Fellow, representative of the IFA at the United Nations Economic and Social Council and directly responsible for the formal relations with the Ageing and Life Course Department, World Health Organization. She holds adjunct academic positions, executive positions on ministerial, government and non-government committees and the corporate sectors internationally and has many years of experience in organizational management, staff development and the analysis of operations leading to improvements in policies, programs and client outcomes in the areas of health, ageing and disability.
(Vice-chair) Bill Cheliak is currently the VP of Business Development of Neurodyn, a start-up neurological research company using slowly progressive animal models of neurodegenerative diseases. Dr. Cheliak is also the co-founder of BNC Pharma, a consulting firm that assists companies in the pharma and biotech industries. Dr. Bill Cheliak is the former VP Business Development at Genizon BioSciences and the former VP Business Development and Alliances at Supratek Pharma. Dr. Cheliak has more than 20 years of experience in the biotechnology sector including executive roles at Cobequid Life Sciences and as President of its ProGeneSys division. Dr. Cheliak has held executive positions in the public sector and is currently a member of several senior committees providing advice and recommendations to the Government of Canada on funding of large national science and infrastructure initiatives. Dr. Cheliak has a Ph.D. in population genetics from the University of Alberta.
Janet Bax is a Program Director at the Council of Canadian Academies. Prior to joining the Council, she served as Executive Director of the Federal Healthcare Partnership Secretariat in the Department of Veterans Affairs. Previously, she worked in the Department of Public Safety where she was responsible for emergency preparedness and recovery, and in various capacities in the Government of Ontario, including the positions of Executive Secretary of the Ontario Quebec Permanent Commission, as a senior representative for Ontario in Brussels, as a special advisor to develop an overseas higher education marketing strategy for the Ministry of Colleges and Universities, and as a director in the Ontario Women’s Directorate. Janet’s substantial career in the federal public service also included positions in the Department of Foreign Affairs, as Director of the Academic Relations Division, and as Consul, Cultural Affairs in New York; in Environment Canada on policy development, climate change and federal/provincial and territorial relations; in Heritage Canada as communications advisor to the minister; and at the Millennium Bureau. Janet has a background in politics and French, having studied at the College of Europe in Belgium, the Sorbonne, the University of London, and York and Trent Universities in Canada.
Bill Borland is presently an Associate with Dillon Consulting Limited in Saint John, New Brunswick. He has held senior environmental management positions with AMEC Environment and Infrastructure, Vice President Canadian Federal Programs (2007 – 2012); J.D. Irving, Limited, Director Environmental Affairs (1989-2007) and NB Power, Manager Environmental Planning (1980-1989). Bill sat on the Boards of the Canadian Water Network (Chair), the Canadian Rivers Institute, NB Research and Productivity Council. He was also a Member of the National Roundtable on the Environment and the Economy (NRTEE) (2001-2005) where he Co-Chaired the Boreal Forest Program and sat on the NRTEE Expert Advisory Committee on Water. He presently sits on the Standing Selection Committee of the Networks of Centres of Excellence and the Boards of ECO Canada (Governance Committee) and Enovex Inc.
Gail Charnley is toxicologist specializing in environmental health risk assessment and risk management science and policy. She has over 30 years of experience in the biological, chemical, and social policy aspects of environmental and public health protection. Dr. Charnley focuses on strategic analysis and risk communication of complex scientific and regulatory issues to both nontechnical and scientific audiences. She works primarily on the safety of chemicals in food, environmental media, work environments, and consumer products. She is a lecturer in the Yale School of Public Health and serves on the National Academy of Sciences’ Board on Environmental Studies and Toxicology. She has been executive director of the Presidential/Congressional Commission on Risk Assessment and Risk Management, director of the Toxicology and Risk Assessment Program at the National Academy of Sciences, and President of the international Society for Risk Analysis. She has a PhD in toxicology from MIT and has been an independent consultant since 1999.
Roxanne Deslauriers has a BSc (Experimental Biology) and PhD (Physical Biochemistry). She is currently the Scientific Director at the Thunder Bay Regional Research Institute (TBRRI). Prior to her work with TBRRI, she was a staff member at the National Research Council (NRC) of Canada (1972 - 2013), where she conducted research in biomedical applications of magnetic resonance and became Principal Research Officer. From 1999 – 2013, she was Director of Research and Director of Strategic Programs for the NRC Institute for Biodiagnostics. Dr. Deslauriers has held Adjunct Professorships at the University of Ottawa, the University of Illinois, the University of Winnipeg and the University of Manitoba as well as lectureships and visiting professor/scholar appointments at the University of Toronto, Harbin Medical University (China) and Queen’s University (Kingston, Canada). She is currently an Adjunct Professor in the Department of Chemistry at Lakehead University and an Associate Professor at the Northern Ontario School of Medicine (NOSM). She has published over 200 peer-reviewed articles and has lectured widely on biomedical applications of magnetic resonance spectroscopy and imaging (MRI). She is a member of national and international science and grant review panels in both North America and Europe, and has mentored scientists and administrators in competitive funding processes in America, Europe and Asia. Dr. Deslauriers is currently Secretary General of the International Society of Magnetic Resonance (ISMAR), a Fellow of the International Society of Magnetic Resonance in Medicine (ISMRM) and was awarded the Queen Elizabeth II Golden Jubilee Medal by the Government of Canada in 2003.
Alistair Duncan, B.Sc., C.P.A - C.A. is co-founder, President and CEO of viDA Therapeutics Inc, a company advancing first-in-class drugs based on inhibitors of the extracellular serine protease, Granzyme B (GzmB), to treat autoimmune and chronic inflammatory diseases. Previously, Alistair was co-founder, Director and served as interim Chief Financial Officer for Agrisoma Biosciences Inc., a company building a high performance crop seeds business for the development of new genetically modified crops for renewable fuels; and co-founder, President and CEO of Chromos Molecular Systems Inc., providing cell line engineering services for quality cell lines for the manufacture of biopharmaceuticals and developing innovative therapies with its Artificial Chromosome Expression (ACE) System and Rapid Expansion Method technologies. Prior to that, he was a Principal with the Ernst & Young Corporate Finance and International Life Sciences Group where he provided high technology and life sciences companies with corporate advisory services. Alistair has served as Past Chairman of the Board of Directors and a Board Member for the Michael Smith Foundation for Health Research, BC Technology Industry Association, BC Research Institute for Children’s and Women’s Health. He is a member of the Institute of Chartered Accountants of British Columbia and holds a B.Sc. in Biochemistry from the University of British Columbia.
Denis Faubert is CEO of the Consortium for Research and Innovation in Aerospace in Québec (CRIAQ) since May 2014 while assuming at the same time the function of CEO of the Canadian Aerospace Research and Innovation Consortium (CARIC) since July 2014. He has previously been the General Manager of the Hydro-Quebec Research Institute (IREQ) for seven years. Within Defence Research and Development Canada, he served as the Director General of the Valcartier Research Centre from 1998 to 2005 and Director General supervising the National Defence Research Program in Ottawa for two years afterwards. He earned an honours Bachelor’s degree in physics from the Royal Military College of Canada and his PhD in Laser Physics from Université Laval. He sits on the Board of Directors of many technical organizations and led a NATO Research Panel on Sensors and Electronics Technology. He has been recognized through many distinctions, including the National Research Council’s prestigious Centennial Scholarship, the Deputy Minister of National Defense’s Innovation Award (2005) and Université Laval’s Faculty of Science Summa-Carrière Award (2008).
David Fung is the chairman and CEO of the ACDEG Group of companies, a global technology integrator, with business partnerships in forest products, clean technologies, chemicals, renewable energy, agrifoods, marine equipment, OEM parts manufacturing and packaging wastes recycling in North America, Europe and Asia. He is a member of the Regulatory Advisory Committee of the Treasury Board of Canada, an “investment champion” for the Canadian Department of Foreign Affairs, Trade and Development, and a member of the Gateway Performance Table of Transport Canada. Dr. Fung is chair of the Chemical Institute of Canada and a strategic advisor of Cycle Capital Management Inc., the largest clean technology venture capital fund in Canada.
Cathy Garner has a life-long dedication to innovation for economic and social improvement and over 20 years of experience in practice. She is founder and current principal of an international consulting network specialising in innovation in cities and university- business partnerships for knowledge exchange. She has worked with clients around the world from Europe to Japan and Australia. She is currently also an Associate of the Council for Industry and Higher Education of the UK; a member of the New Club of Paris and an advisor to the World Capital Institute in Mexico on knowledge-city development. As Chief Executive of Manchester: Knowledge Capital for six years she built a globally recognised partnership for innovation by bridging the boundaries across business, universities and government. Her partnership building skills and style of leadership delivered success by inspiring and supporting innovation across projects and sectors. Manchester achieved global recognition for this effort by being named most admired Knowledge City in 2009. With a background in policy development and research in social housing, regeneration and community development, she has worked in economic development, urban systems, innovation, and knowledge transfer and business entrepreneurship. Her initial academic research career was in school educational performance. In the UK she served on the Strategic Advisory Board for Intellectual Property between 2008 and 2010, was a member of the Cabinet Office Innovators’ Council in 2009. Cathy has served as a non-executive director on number of public and private sector Boards and is a Fellow of the Royal Statistical Society and a Fellow of the Royal Society of Arts. In 2002 Cathy established an international charity to address the health needs of the global poor through creative intellectual property solutions, working with the Rockefeller Foundation, international NGO’s, multinational corporations and universities worldwide. She continues this work in a volunteer capacity. Previously Cathy established and ran the Research and Enterprise Office at the University of Glasgow in Scotland where she led the establishment of the Scottish Institute for Enterprise and was a founder director of the Scottish North American Business Council. She was a member of the Association of University Technology Managers (AUTM) in the USA and served as their inaugural Vice President for International Relations.
Michael Gibbons is Honorary Professorial Fellow in Science and Technology Policy Research with the University of Sussex. Former appointments include Director of the Science Policy Research Unit at Sussex University and Secretary General of the Association of Commonwealth Universities. Prior to these appointments he was Founding Director of the Programme of Policy Research in Engineering Science and Technology at the University of Manchester and Director of Research and Technology Transfer in that University. Dr. Gibbons has an active research interest in science and technology policy generally but has additionally carried out research in the process of technological innovation in industry and the evaluation of research. He is co-author with colleagues of two major books on the nature of contemporary science: New Modes of Knowledge Production and Re-thinking Science, which have arguably set the agenda for much current science policy debate. His work has been vigorously taken up by the South African authorities who have adopted the notion of Mode 2 research as a guiding concept during the current, and ongoing, transformation of the South African higher education system. From 2000 to 2003, he was a member of the UK Economic and Social Research Council and Chair of its Research Priorities Board. From 2004, he was Chair of the Board of Quest University, Canada’s first secular, private, not-for-profit university, based in Squamish, British Columbia. In 2004 he became a Member of the Order of the British Empire (MBE) for services to Higher Education and was awarded the Queen’s Jubilee Medal for excellence in research by the government of Canada.
Greg Hammond has over 35 years of infectious disease experience in the areas of research, clinical care, public health policy and program development. He has served in many senior capacities and leadership roles at provincial and national levels. Dr. Hammond received his training at the universities of McGill, Alberta, Toronto and Manitoba, as well as at the Centres for Disease Control and Prevention in Atlanta, Georgia. He is a Professor in the Departments of Medical Microbiology and Medicine, University of Manitoba. Dr. Hammond has broad experience in public service including: Head, Virus Detection Unit, and Director, Cadham Provincial Public Health Laboratory, Manitoba. He was a member of the National Advisory Committee on Immunization (NACI). He has served as Director of Communicable Disease Control and Director of the Public Health Branch (Manitoba Health). He was a member of the WHO’s Technical Logistics Advisory Committee (TLAC) on immunization. He was the provincial co-chair of the National Immunization Strategy and subsequently the Canadian Immunization Committee. Dr. Hammond is a clinical consultant with the Section of Infectious Diseases, Department of Medicine, Health Sciences Centre and Grace General Hospital. Dr. Hammond is a board member and Chair of the Nominations Committee of the Pan Provincial Vaccine Enterprise (PREVENT), which works with three universities (British Columbia, Dalhousie, and Saskatchewan) to accelerate early candidate vaccine development. He was the Scientific Director of the Alliance Coordinating Office (ACO) of the Canadian HIV Vaccine Initiative (CHVI) in Winnipeg, 2011-2014. He is the Executive Director of the Manitoba Medical Services Foundation (MMSF) of the Manitoba Blue Cross, which provides research and educational grants to new health researchers in Manitoba.
Hugh Ilyine is a biomedical entrepreneur with more than 25 years’ international experience in company leadership in multinational corporations and biotechnology companies, from start-up through to listings on UK and Australian Stock Exchanges. He has covered food and agriculture bio-ingredients, stem cells, biosimilar therapeutics and molecular diagnostic fields from founder through to CEO and company director roles. Hugh has worked previously as a consultant and expert adviser to the Australian, UK and Canadian governments in the fields of stem cell research and regenerative medicine, serving also on the UK and Scottish Stem Cell Networks in advisory roles. He acts currently as an expert reviewer for the UK Technology Strategy Board. He previously enjoyed over 17 years with the Rhône-Poulenc group, including work in the UK, France, Indonesia and Australia. He is a co-founder, CEO and Executive Director of DestiNA Genomics Ltd, a spin-out molecular diagnostic company from the University of Edinburgh; a founder and former CEO of Profactor Pharma Ltd, developing biosimilar therapeutics; and a non-executive director of Regenerys Ltd, a company formed to deliver cell-based product solutions for serious burns, chronic wounds and post-mastectomy breast reconstructions. Hugh has Australian and British dual nationality, is bi-lingual (English and French), and currently lives in Scotland He has a BSc in Applied Science from the University of New South Wales, Sydney, and a marketing degree from Monash University, Melbourne.
John Leggat was the Assistant Deputy Minister (Science & Technology) of the Department of National Defence and the Chief Executive Officer of Defence Research and Development Canada (DRDC). In this capacity, he led DRDC, which provides national leadership in defence science, and furnishes scientific advice and products to the Canadian Forces and the Department of National Defence. During his scientific career, Dr. Leggat has held a number of appointments in defence R&D. As Director General of DRDC’s Ottawa research centre from 1994-1997, he directed a program that addressed radar systems, electronic warfare, communications and space systems. From 1990 to 1994 he was responsible for the technology development program for the Department of National Defence. Prior to this appointment, he spent 14 years at the DRDC Atlantic research centre where he carried out and led research in the area of ship and submarine technology pertaining to noise reduction, hydromechanics, ship structures and materials. Dr. Leggat is a Past President of the International Council of Academies of Engineering and Technological Sciences. He is a Past President of the Canadian Academy of Engineering. He is a member of the Deputy Minister’s Science Advisory Board of the Department of Natural Resources. He is a past President of the Alumni Association of the Royal Military Colleges of Canada.
Robin Mansell is Professor of new media and the internet and former Head of the Department of Media and Communications, London School of Economics and Political Science (2006-09). She served as President of the International Association for Media and Communication Research (2004-08), Scientific Chair of the Euro Communications Policy Research Conference (2008-14) and as Director of Research at the Science Policy Research Unit - SPRU (1999-2000) at the University of Sussex, where she was also Professor of information and communication technology policy (1995-2000. Reader 1988-94). She is interested in the structure of communications and media markets, the sources of regulatory effectiveness and failure, and issues of Internet governance, including intellectual property rights, privacy and security. She is author of many scholarly articles and books, including Imagining the Internet: Communication, Innovation and Governance (Oxford University Press, 2012) and The Handbook of Global Media and Communication (co-edited with M. Raboy, Wiley-Blackwell 2011).
Chris Mason is a Professor of Regenerative Medicine Bioprocessing in the Advanced Centre for Biochemical Engineering, University College London working on the clinical translation and commercialization of cell and gene therapies, and tissue-engineered products. His multidisciplinary track record spans biopharmaceuticals, medical devices and information technology, in basic science, clinical medicine, bioprocessing, regulation, healthcare economics, reimbursement and business. Current activities include: Chair of the BioIndustry Association (BIA) Regenerative Medicine and Cell Therapy Industry Group, Senior Editor of Regenerative Medicine journal, Trustee of the UK Stem Cell Foundation, Founder and Director of the London Regenerative Medicine Network, President of the Regenerative Medicine Coalition, member of the UK Department of Health Regenerative Medicine Expert Group, member of the UK Clinical Trials, Biologicals & Vaccines Expert Advisory Group of the Commission on Human Medicines, and member of the United States Pharmacopeia (USP) Monographs - Biologics & Biotechnology Expert Committee.
Julie McDowell is the President of TARIS Incorporated, where she advises social and healthcare entrepreneurs and innovators, and the organizations that serve them. TARIS also invests in start up ventures that use commercial solutions to address global health challenges. These include Magnusmode Ltd., a company that produces software for young adults with cognitive special needs, and ChipCare Corporation that is developing portable blood testing technology for use in low resource settings. She serves as Board Chair of Magnusmode. Since 2003, Julie has held a number of leadership and volunteer positions, with a focus on global health and disability including Member of the Investment Committee and Scientific Advisory Board of Grand Challenges Canada, Member of the USAID Saving Lives at Birth Investment Panel, Chair of the Canadian Abilities Foundation and Regional Director for ORBIS Canada. She has also been an active member of the Canadian angel investment community and is a former Board Chair of Toronto based Maple Leaf Angels. Prior to 2003, Julie enjoyed a successful business career in the apparel and textile industry, and held sales and management positions in retailing, manufacturing, and small business consulting. She also founded, grew and sold a successful promotional merchandising and uniform company with operations in Canada and the United States. Julie holds a Master of Science in Human Ecology from Cornell University in Ithaca, New York.
Barbara Mittleman is an internist and rheumatologist with substantial clinical, bench and administrative experience. She earned B.A., and M.D. degrees from the University of Pittsburgh where she also completed residency and fellowship training in Internal Medicine and Rheumatology. She then came to NIH for additional post-doctoral training in cellular immunology, focusing the autoimmunity and pathobiology of systemic lupus erythematosus. In 1995 she was named the inaugural Director of the NIH's Program on Public-Private Partnerships, where she is charged with developing and promulgating policy, brokering interactions among a wide variety of government and non-government partners, and in the development and execution of partnerships which promote the NIH's public health mission. She lectures widely on partnership-related topics and has provided advice and best practices based on NIH's experience to organizations including other Universities, government agencies, foundations and advocacy groups, companies and trade organizations, and others. She also serves on the CIHR Commercialization Advisory Board.
John Neate is an entrepreneurial senior executive who has helped organizations navigate the complex challenges of technology innovation, leading to business growth and stakeholder buy-in. He has a unique blend of technical, managerial and operational expertise combined with strategic planning acumen, and demonstrated ability to mobilize resources. John is an experienced builder of positive alliances with businesses and organizations across Canada and internationally, while being a strong communicator, motivational leader, and effective negotiator. John is co-founder of VerifiGlobal, a comprehensive platform for performance measurement and verification across multiple sectors and areas of expertise. He has been a key Canadian contributor to international efforts aimed at encouraging mutual recognition and acceptance of performance testing and verification information across multiple jurisdictions. John has also played a leadership role in the identification and assessment of information gaps, research needs and effective solutions for long-term management of used nuclear fuel in Canada. He is Former President and Chief Operating Officer of Water Technology International Corporation, an employee-owned research services company, and a founding director of the Ontario Centre for Environmental Technology Advancement.
J. Robert S. Prichard is chairman of Torys LLP, a leading international business law firm with offices in Toronto, Calgary, Montréal and New York. He is also chairman of the Bank of Montreal and chair of Metrolinx, the regional transportation agency for the Greater Toronto and Hamilton area. Prior to joining Torys in 2010, Rob had careers as a law professor, academic leader and business leader. He was a professor of law at the University of Toronto from 1976 to 2001, specializing in law and economics and served as dean of the Faculty of Law at the University of Toronto from 1984 to 1990. Rob served as the 13th president of the University of Toronto from 1990 to 2000. Rob’s business experience includes serving from 2002 to 2009 as president and CEO of Torstar Corporation, a leading Canadian media company with newspaper and book publishing businesses. He currently serves as a director of Onex Corporation and George Weston Ltd. (as Lead Director). In the volunteer sector, Rob serves as a trustee of the Hospital for Sick Children and also serves as a member of Ontario’s Economic Advisory Panel. Rob has previously served as Vice Chair of Canada’s Science, Technology and Innovation Council, chair of the Visiting Committee for Harvard Law School and as a member of Canada’s Economic Advisory Council. Rob studied honours economics at Swarthmore College, received his MBA (Dean’s List) in finance and international business from the University of Chicago and earned law degrees from the University of Toronto (Gold Medalist) and Yale University (Viscount Bennett Fellow). Rob has been recognized by appointment as an officer of the Order of Canada, a member of the Order of Ontario and a Fellow of the Royal Society of Canada. He has received honorary degrees from 10 colleges and universities in Canada and the United States, the David Smith Award for contributions to public policy in higher education in Canada, and the Champion of Public Education award from the Learning Partnership.
Paul Root Wolpe, Ph.D. is the Asa Griggs Candler Professor of Bioethics, Raymond Schinazi Distinguished Research Professor of Jewish Bioethics, Professor of Medicine, Pediatrics, Psychiatry, Neuroscience and Biological Behavior, and Sociology, and the Director of the Center for Ethics at Emory University. Dr. Wolpe also serves as the Senior Bioethicist at the National Aeronautics and Space Administration (NASA). He is an editor of the American Journal of Bioethics (AJOB) and Editor-in-Chief of AJOB-Neuroscience, and sits on the editorial boards of over a dozen professional journals in medicine and ethics. Dr Wolpe is a past President of the American Society for Bioethics and Humanities, a Fellow of the Hastings Center, and a Fellow of the College of Physicians of Philadelphia, the country’s oldest medical society. Dr. Wolpe publishes in sociology, medicine, and bioethics, and has contributed to a variety of encyclopedias on bioethical issues. His work focuses on the social, religious, and ideological impact of technology on the human condition. Considered one of the founders of the field of neuroethics, which examines the ethical implications of neuroscience, he also writes about other emerging technologies, such as genetic engineering and functional prosthetics. His teaching and publications range across multiple fields of bioethics and sociology, including death and dying, genetics and eugenics, clinical care, sexuality and gender, mental health and illness, alternative medicine, and bioethics in extreme environments such as space.